Last Price
957.00
Today's Change
+19.39 (2.06%)
Day's Change
926.94 - 958.02
Trading Volume
514,613
Market Cap
103 Billion
Shares Outstanding
108 Million
Avg Volume
472,833
Avg Price (50 Days)
944.28
Avg Price (200 Days)
867.66
PE Ratio
27.52
EPS
34.77
Earnings Announcement
14-Jun-2024
Previous Close
937.61
Open
926.94
Day's Range
926.94 - 958.02
Year Range
684.81 - 998.33
Trading Volume
525,885
1 Day Change
2.07%
5 Day Change
8.36%
1 Month Change
2.13%
3 Month Change
1.25%
6 Month Change
17.15%
Ytd Change
5.75%
1 Year Change
26.94%
3 Year Change
97.25%
5 Year Change
178.01%
10 Year Change
220.09%
Max Change
4430.18%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.